Compare 3M Company (MMM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Vertex Pharmaceuticals Incorporated — how do they compare? 3M Company trades at $160.84 (market cap $84.36B), while Vertex Pharmaceuticals Incorporated trades at $511.11 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and 3M Company pays a 1.91% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MMM | VRTX | |
|---|---|---|
Market Cap | $84.36B | $127.55B |
Volume | 2,325,301 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $183.79 | $557.96 |
52-Week Low | $141.10 | $407.37 |
Typical Hold Time | 169 Days | 120 Days |
Enterprise Value | $93.58B | $121.68B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $161.26, down 0.53% with a bearish technical signal despite strong Q2 2026 earnings beats. The company shows robust profitability with 82.77% ROE and 11.9% net margins, though revenue has declined from 2022 peaks. Analyst consensus is mixed with 48% buy ratings and a $191 price target, while recent news highlights operational improvements and litigation management progress.
The outlook balances strong fundamentals against technical weakness and consumer segment challenges. Investment opportunity lies in continued margin expansion and industrial growth, while risks include high debt levels, soft retail demand, and ongoing PFAS litigation costs that could pressure cash flow.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
